Cargando…
Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor
Drug-induced immune hemolytic anemia (DIIHA) is an uncommon side effect of pharmacologic intervention. A rare mediator of DIIHA, carboplatin is an agent used to treat many pediatric cancers. We describe here, the first case of fatal carboplatin induced DIIHA in a pediatric patient and a brief review...
Autores principales: | Haley, Kristina M, Russell, Thomas B, Boshkov, Lynn, Leger, Regina M, Garratty, George, Recht, Michael, Nazemi, Kellie J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031206/ https://www.ncbi.nlm.nih.gov/pubmed/24868179 http://dx.doi.org/10.2147/JBM.S59192 |
Ejemplares similares
-
Piperacillin-Induced Immune Hemolytic Anemia in an Adult with Cystic Fibrosis
por: Bandara, Mahesh, et al.
Publicado: (2010) -
Carboplatin Induced Fatal Autoimmune Hemolytic Anemia: First Reported Case
por: Dacha, Sunil, et al.
Publicado: (2010) -
Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
por: Robertson, Jake C, et al.
Publicado: (2021) -
Fatal hemolytic anemia associated with metformin: A case report
por: Packer, Clifford D, et al.
Publicado: (2008) -
A Fetal Hemolytic Anemia in a Child with Cytomegalovirus Infection
por: Hosseeini, S, et al.
Publicado: (2014)